Sangamo Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
13/03/2024 14:49
* Sangamo Therapeutics Inc SGMO.OQ reported a quarterly
adjusted
loss of 34 cents per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -32 cents. The mean expectation of nine analysts for the
quarter was for a loss of 26 cents per share. Wall Street
expected results to range from -37 cents to -18 cents per share.
* Revenue fell 92.5% to $2.04 million from a year ago;
analysts
expected $8.11 million.
* Sangamo Therapeutics Inc's reported EPS for the quarter
was a
loss of 34 cents.
* The company reported a quarterly loss of $60.3 million.
* Sangamo Therapeutics Inc shares had risen by 58.5% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Sangamo
Therapeutics Inc is $2.50
This summary was machine generated from LSEG data March 13 at
02:48 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.26 -0.34 Missed
Sep. 30 2023 -0.32 -0.59 Missed
Jun. 30 2023 -0.34 -0.66 Missed
Mar. 31 2023 -0.33 0.12 Beat